Developer docs
API playgroundTry for free, no card

Search company profiles

BioSymetrics

Full company profile

uuid0000zap

Namestring
BioSymetrics
Legal namestring
BioSymetrics Inc.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

BioSymetrics is a phenomics-driven AI drug discovery company that builds target identification and precision-medicine programs by connecting human disease phenotype and genotype data to in vivo validation. Its core platform, Elion, combines machine-learning predictions with high-content zebrafish phenotypic screening in 96-well plates, supported by the patent-pending Contingent AI™ framework for denoising and integrating clinical data and the Phenograph knowledge graph that maps phenotypes to genes to diseases to drugs across model systems. The platform is reported to leverage more than 77 million longitudinal patient records and over 1 million genomic profiles, with the KCC2 Epilepsy program generating over 12,000 zebrafish videos analyzed via proprietary computer vision at 15,000+ data points each.

The company operates as a B2B enterprise platform with no consumer distribution, monetizing through co-development agreements, licensing and royalty structures, and select non-dilutive grants. Commercial customers and partners include Pfizer, Deerfield Management (under a five-year joint venture), Sema4 (up to 10 therapeutic programs), Janssen Pharmaceuticals, BrainStorm Therapeutics, Northwell Health, and Brigham and Women's Hospital. Recent expansion into U.S. defense applications is anchored by the Pathfinder Consortium, targeting the $400M–$1.2B per-program federal countermeasure procurement market. Following the April 2025 close of its merger with Renovaro, BioSymetrics operates as a wholly owned subsidiary of Lunai Bioworks (NASDAQ: LNAI), with a remote-first workforce of 11–50 employees concentrated in the New York/Boston and Toronto areas.

Short descriptiontext

BioSymetrics is a phenomics-driven AI drug discovery company that combines proprietary machine learning, the Phenograph knowledge graph, and zebrafish in vivo validation to identify higher-confidence therapeutic targets for pharmaceutical, biotech, and U.S. defense partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, phenomics platform, target identification, zebrafish screening, precision medicine
Industry5 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery Platform
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Defense Collaboration Revenue
TypeSubscription Recurring
Description

Revenue-generating defense-focused collaboration through BioSymetrics for AI-enabled chemical threat assessment with government/biotech partners. Initial engagement underway with additional discussions ongoing.

biospace.com
2Pharmaceutical Partnership Agreements
TypeLicensing Royalties
Description

Co-development and pharmaceutical partnering structures for development-ready neurology programs. Includes licensing agreements and downstream co-development structures with pharmaceutical companies.

biospace.com
3NIH Grant Funding
TypeProfessional Services
Description

$1.85 million NIH STTR grant awarded to BioSymetrics and Brigham and Women's Hospital for AI-powered alcohol use disorder therapeutic discovery platform.

pharmiweb.com
4Rare Disease Data Collaboration
TypeSubscription Recurring
Description

Revenue-generating partnerships with pharmaceutical companies enabled by patient cohort development for rare neurological disorders through Geneial collaboration.

stocktitan.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Elion
Description

The phenomics-driven drug discovery and development platform that uses machine learning predictions and in vivo validation with zebrafish models.

biosymetrics.com
+1 more record
Core offering1 text field

BioSymetrics operates the Elion phenomics-driven drug discovery and development platform that connects disease phenotype and genotype data between humans and model systems, using machine learning to predict novel gene targets and coupling predictions with high-content in vivo validation using zebrafish phenotypic models. The platform integrates clinical data, genomic profiles, and experimental readouts through the patented Contingent AI™ framework and the Phenograph knowledge graph, targeting pharmaceutical partners in neurological, cardiometabolic, and rare disease programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Twice the likelihood of clinical success for targets grounded in human genetic evidence
+1 more record
Product overview1 text field

BioSymetrics is a phenomics-driven AI drug discovery company offering a unified platform centered on the Elion platform, which integrates machine learning predictions with in vivo validation. The core technology stack includes Contingent AI™ (their patented AI iteration framework for denoising and integrating clinical data), the Phenograph (a knowledge linkage map connecting phenotypes to genes to drugs), and a Zebrafish Phenotypic Validation Platform for in vivo target validation. These components work together to connect disease phenotype and genotype data between humans and model systems, enabling higher-confidence target discovery and precision medicine development faster than traditional reductionist approaches.

Product and service2 records
1Elion Platform
CategoryAI Drug Discovery Platform
Description

The phenomics-driven drug discovery and development platform that connects disease phenotype and genotype data between humans and model systems, uses machine learning to make predictions, and couples with high-content in vivo validation using zebrafish models. For pharmaceutical and biotech partners seeking AI-powered target discovery.

2Zebrafish Phenotypic Validation Platform
CategoryIn Vivo Phenotypic Validation
Description

In vivo validation platform using zebrafish phenotypic models with scalable experimentation in 96-well plates and computer vision analysis, enabling high-content phenotypic readouts within days of gene manipulation. For pharmaceutical researchers seeking rapid in vivo validation of AI-predicted targets.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-29
Description

Strategic collaboration to jointly discover and advance novel therapeutic targets for neurological diseases, beginning with rare genetic epilepsies and Parkinson's disease. Supported by LouLou Foundation grant. Combines BioSymetrics' AI-driven target discovery and in vivo zebrafish validation with BrainStorm's proprietary human-derived organoid systems.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-16
Description

Non-binding Letter of Intent for strategic collaboration focused on converting patient-generated data into trial-ready cohorts for rare neurological disorders. Aims to integrate datasets across multiple patient registries for pharmaceutical partnerships.

3Pathfinder Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-19
Description

National academic-industry alliance through BioSymetrics designed to consolidate U.S. chemical warfare preparedness resources into unified infrastructure for accelerated medical countermeasure development. Includes Harvard, Brigham and Women's Hospital, University of Utah, Purdue, and University of Colorado. Targets $400M-$1.2B federal procurement market per program with 3-year development timeline.

aijourn.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-16
Description

Multi-institutional research collaboration leading to identification of serum protein biomarkers predictive of disease progression in Duchenne Muscular Dystrophy. Validated RGMA, ART3, and ANTXR2 as disease progression indicators.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-11
Description

NIH STTR grant collaboration ($1.85M) to develop AI-powered platform for alcohol use disorder therapeutic discovery. Uses AI and zebrafish screening to accelerate AUD treatment development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-26
Description

Five-year joint venture to accelerate advancement of new therapeutics with initial focus on cardiovascular and neurological diseases. Combines BioSymetrics' AI-powered target discovery with Deerfield's drug discovery and commercial modeling capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-22
Description

Strategic partnership leveraging Sema4's Centrellis health intelligence platform and BioSymetrics' Elion phenotypic drug discovery platform. Up to 10 therapeutic programs in cardiovascular, rare and neurological diseases. Initial focus on atherosclerosis.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-08-19
Description

Collaboration to predict onset and severity of COVID-19 using machine learning. Used Contingent-AI engine across several projects to characterize high-risk populations and identify markers for clinical phenotype.

9Humanigen
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership supporting Humanigen's Phase 3 study of lenzilumab for COVID-19. Applied phenotypic-driven drug discovery to investigate patient subsets and identify CRP as biomarker for precision use of lenzilumab.

biosymetrics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for ARDS research and COVID-19 phenogrouping studies. Co-authored research on COVID-19 ARDS patient mortality factors.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Computational chemistry and physics-based drug design platform serving pharma partners. Comparable in monetizing drug-discovery software capabilities through enterprise and partnership deals.

TypeDirect peer
Description

AI + quantum physics drug discovery platform with major pharma partnerships. Comparable in serving pharma R&D with computational prediction engines and co-development deal structures.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput wet-lab experimentation with ML to identify novel targets. Directly comparable in using phenotypic data and in vivo validation to complement in silico predictions, and a leader in the same category BioSymetrics competes in.

TypeDirect peer
Description

ML-driven drug discovery platform that integrates engineered in vitro disease models with patient genomics data. Closely comparable to BioSymetrics' combination of clinical-scale data integration and biological validation for target discovery.

TypeDirect peer
Description

Pioneer in AI-driven small-molecule discovery using structure-based design and ML. BioSymetrics' Chief Strategy Officer previously worked at Atomwise, and both companies pursue pharma partnerships for AI-discovered therapeutics.

TypeDirect peer
Description

End-to-end AI drug discovery company with clinical-stage assets and major pharma partnerships. Comparable in deploying AI to compress target-to-candidate timelines and in building pharma co-development deals.

TypeEmerging player
Description

AI platform for immune-system disease modeling and drug discovery, focused on pharma data partnerships. Comparable in using patient-derived multi-omics data to support pharma target and biomarker decisions.

TypeEmerging player
Description

AI-driven oncology drug development company using machine learning to identify responder populations and repurpose therapeutics. Comparable in applying ML/AI to drug-discovery pipelines with pharma partnership economics.

TypeEmerging player
Description

AI-driven drug discovery company leveraging patient-derived data and ML to identify novel indications and drug candidates. Comparable in data-driven target prioritization and pharma partnering model.

TypeBroad incumbent
Description

Large synthetic biology and cell-engineering platform that has built a partner network (in which BioSymetrics is an inaugural member). Adjacent rather than direct overlap, but both pursue data-rich, partner-driven biology discovery for pharma and government.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioSymetrics

AI Drug Discovery Platformbiosymetrics.com

BioSymetrics is a phenomics-driven AI drug discovery company that combines proprietary machine learning, the Phenograph knowledge graph, and zebrafish in vivo validation to identify higher-confidence therapeutic targets for pharmaceutical, biotech, and U.S. defense partners.

What BioSymetrics does

BioSymetrics is a phenomics-driven AI drug discovery company that builds target identification and precision-medicine programs by connecting human disease phenotype and genotype data to in vivo validation. Its core platform, Elion, combines machine-learning predictions with high-content zebrafish phenotypic screening in 96-well plates, supported by the patent-pending Contingent AI™ framework for denoising and integrating clinical data and the Phenograph knowledge graph that maps phenotypes to genes to diseases to drugs across model systems. The platform is reported to leverage more than 77 million longitudinal patient records and over 1 million genomic profiles, with the KCC2 Epilepsy program generating over 12,000 zebrafish videos analyzed via proprietary computer vision at 15,000+ data points each.

The company operates as a B2B enterprise platform with no consumer distribution, monetizing through co-development agreements, licensing and royalty structures, and select non-dilutive grants. Commercial customers and partners include Pfizer, Deerfield Management (under a five-year joint venture), Sema4 (up to 10 therapeutic programs), Janssen Pharmaceuticals, BrainStorm Therapeutics, Northwell Health, and Brigham and Women's Hospital. Recent expansion into U.S. defense applications is anchored by the Pathfinder Consortium, targeting the $400M–$1.2B per-program federal countermeasure procurement market. Following the April 2025 close of its merger with Renovaro, BioSymetrics operates as a wholly owned subsidiary of Lunai Bioworks (NASDAQ: LNAI), with a remote-first workforce of 11–50 employees concentrated in the New York/Boston and Toronto areas.

BioSymetrics firmographics

Firmographics
Name
BioSymetrics
Legal name
BioSymetrics Inc.
Website
https://biosymetrics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
BioSymetrics is a phenomics-driven AI drug discovery company that combines proprietary machine learning, the Phenograph knowledge graph, and zebrafish in vivo validation to identify higher-confidence therapeutic targets for pharmaceutical, biotech, and U.S. defense partners.
Ownership category
akta.pro rank

BioSymetrics industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • AI drug discovery
  • Phenomics platform
  • Target identification
  • Zebrafish screening
  • Precision medicine

Where BioSymetrics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

BioSymetrics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Defense Collaboration Revenue: Revenue-generating defense-focused collaboration through BioSymetrics for AI-enabled chemical threat assessment with government/biotech partners. Initial engagement underway with additional discussions ongoing.
  2. Pharmaceutical Partnership Agreements: Co-development and pharmaceutical partnering structures for development-ready neurology programs. Includes licensing agreements and downstream co-development structures with pharmaceutical companies.
  3. NIH Grant Funding: $1.85 million NIH STTR grant awarded to BioSymetrics and Brigham and Women's Hospital for AI-powered alcohol use disorder therapeutic discovery platform.
  4. Rare Disease Data Collaboration: Revenue-generating partnerships with pharmaceutical companies enabled by patient cohort development for rare neurological disorders through Geneial collaboration.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

BioSymetrics product offering

Product offering

Core offering

BioSymetrics operates the Elion phenomics-driven drug discovery and development platform that connects disease phenotype and genotype data between humans and model systems, using machine learning to predict novel gene targets and coupling predictions with high-content in vivo validation using zebrafish phenotypic models. The platform integrates clinical data, genomic profiles, and experimental readouts through the patented Contingent AI™ framework and the Phenograph knowledge graph, targeting pharmaceutical partners in neurological, cardiometabolic, and rare disease programs.

Product overview

BioSymetrics is a phenomics-driven AI drug discovery company offering a unified platform centered on the Elion platform, which integrates machine learning predictions with in vivo validation. The core technology stack includes Contingent AI™ (their patented AI iteration framework for denoising and integrating clinical data), the Phenograph (a knowledge linkage map connecting phenotypes to genes to drugs), and a Zebrafish Phenotypic Validation Platform for in vivo target validation. These components work together to connect disease phenotype and genotype data between humans and model systems, enabling higher-confidence target discovery and precision medicine development faster than traditional reductionist approaches.

Differentiator

Problem solved

Functional benefit

Brands

  • Elion: The phenomics-driven drug discovery and development platform that uses machine learning predictions and in vivo validation with zebrafish models.
  • Contingent AI

Products and services

  • Elion Platform The phenomics-driven drug discovery and development platform that connects disease phenotype and genotype data between humans and model systems, uses machine learning to make predictions, and couples with high-content in vivo validation using zebrafish models. For pharmaceutical and biotech partners seeking AI-powered target discovery.
  • Zebrafish Phenotypic Validation Platform In vivo validation platform using zebrafish phenotypic models with scalable experimentation in 96-well plates and computer vision analysis, enabling high-content phenotypic readouts within days of gene manipulation. For pharmaceutical researchers seeking rapid in vivo validation of AI-predicted targets.

Quantifiable outcome

  • Twice the likelihood of clinical success for targets grounded in human genetic evidence
  • +1 more outcomes

Companies that use BioSymetrics

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles3 records

BioSymetrics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature5 records

BioSymetrics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • BrainStorm TherapeuticscoreStrategic or Co-development Partner · 29 May 2026Strategic collaboration to jointly discover and advance novel therapeutic targets for neurological diseases, beginning with rare genetic epilepsies and Parkinson's disease. Supported by LouLou Foundation grant. Combines BioSymetrics' AI-driven target discovery and in vivo zebrafish validation with BrainStorm's proprietary human-derived organoid systems.
  • GeneialminorStrategic or Co-development Partner · 16 April 2026Non-binding Letter of Intent for strategic collaboration focused on converting patient-generated data into trial-ready cohorts for rare neurological disorders. Aims to integrate datasets across multiple patient registries for pharmaceutical partnerships.
  • Pathfinder ConsortiumcoreStrategic or Co-development Partner · 19 March 2026National academic-industry alliance through BioSymetrics designed to consolidate U.S. chemical warfare preparedness resources into unified infrastructure for accelerated medical countermeasure development. Includes Harvard, Brigham and Women's Hospital, University of Utah, Purdue, and University of Colorado. Targets $400M-$1.2B federal procurement market per program with 3-year development timeline.
  • Leiden University Medical CenterminorStrategic or Co-development Partner · 16 October 2025Multi-institutional research collaboration leading to identification of serum protein biomarkers predictive of disease progression in Duchenne Muscular Dystrophy. Validated RGMA, ART3, and ANTXR2 as disease progression indicators.
  • Brigham and Women's HospitalminorStrategic or Co-development Partner · 11 September 2025NIH STTR grant collaboration ($1.85M) to develop AI-powered platform for alcohol use disorder therapeutic discovery. Uses AI and zebrafish screening to accelerate AUD treatment development.
  • Deerfield ManagementcoreStrategic or Co-development Partner · 26 October 2022Five-year joint venture to accelerate advancement of new therapeutics with initial focus on cardiovascular and neurological diseases. Combines BioSymetrics' AI-powered target discovery with Deerfield's drug discovery and commercial modeling capabilities.
  • Sema4coreStrategic or Co-development Partner · 22 February 2022Strategic partnership leveraging Sema4's Centrellis health intelligence platform and BioSymetrics' Elion phenotypic drug discovery platform. Up to 10 therapeutic programs in cardiovascular, rare and neurological diseases. Initial focus on atherosclerosis.
  • Janssen PharmaceuticalsminorStrategic or Co-development Partner · 19 August 2020Collaboration to predict onset and severity of COVID-19 using machine learning. Used Contingent-AI engine across several projects to characterize high-risk populations and identify markers for clinical phenotype.
  • HumanigenminorStrategic or Co-development PartnerPartnership supporting Humanigen's Phase 3 study of lenzilumab for COVID-19. Applied phenotypic-driven drug discovery to investigate patient subsets and identify CRP as biomarker for precision use of lenzilumab.
  • Northwell HealthminorStrategic or Co-development PartnerPartnership for ARDS research and COVID-19 phenogrouping studies. Co-authored research on COVID-19 ARDS patient mortality factors.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

BioSymetrics competitors and assessment

Company assessment

Direct peers

  • Schrödinger: Computational chemistry and physics-based drug design platform serving pharma partners. Comparable in monetizing drug-discovery software capabilities through enterprise and partnership deals.
  • XtalPi: AI + quantum physics drug discovery platform with major pharma partnerships. Comparable in serving pharma R&D with computational prediction engines and co-development deal structures.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput wet-lab experimentation with ML to identify novel targets. Directly comparable in using phenotypic data and in vivo validation to complement in silico predictions, and a leader in the same category BioSymetrics competes in.
  • Insitro: ML-driven drug discovery platform that integrates engineered in vitro disease models with patient genomics data. Closely comparable to BioSymetrics' combination of clinical-scale data integration and biological validation for target discovery.
  • Atomwise: Pioneer in AI-driven small-molecule discovery using structure-based design and ML. BioSymetrics' Chief Strategy Officer previously worked at Atomwise, and both companies pursue pharma partnerships for AI-discovered therapeutics.
  • Exscientia: End-to-end AI drug discovery company with clinical-stage assets and major pharma partnerships. Comparable in deploying AI to compress target-to-candidate timelines and in building pharma co-development deals.

Emerging players

  • CytoReason: AI platform for immune-system disease modeling and drug discovery, focused on pharma data partnerships. Comparable in using patient-derived multi-omics data to support pharma target and biomarker decisions.
  • Lantern Pharma: AI-driven oncology drug development company using machine learning to identify responder populations and repurpose therapeutics. Comparable in applying ML/AI to drug-discovery pipelines with pharma partnership economics.
  • twoXAR Pharmaceuticals: AI-driven drug discovery company leveraging patient-derived data and ML to identify novel indications and drug candidates. Comparable in data-driven target prioritization and pharma partnering model.

Broad incumbents

  • Ginkgo Bioworks: Large synthetic biology and cell-engineering platform that has built a partner network (in which BioSymetrics is an inaugural member). Adjacent rather than direct overlap, but both pursue data-rich, partner-driven biology discovery for pharma and government.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BioSymetrics social profiles

Digital presence

BioSymetrics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioSymetrics leadership team

Management profile

Number of profiles

Profiles12 records

BioSymetrics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioSymetrics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioSymetrics

What does BioSymetrics do?

BioSymetrics operates the Elion phenomics-driven drug discovery and development platform that connects disease phenotype and genotype data between humans and model systems, using machine learning to predict novel gene targets and coupling predictions with high-content in vivo validation using zebrafish phenotypic models. The platform integrates clinical data, genomic profiles, and experimental readouts through the patented Contingent AI™ framework and the Phenograph knowledge graph, targeting pharmaceutical partners in neurological, cardiometabolic, and rare disease programs.

Is BioSymetrics a public or private company?

BioSymetrics is a private company. It is classified as corporate owned and is currently operating.

When was BioSymetrics founded?

BioSymetrics was founded in 2016. It employs 11 to 50 people.

Where is BioSymetrics based?

BioSymetrics is headquartered in Boston, United States, in the North America region.

How does BioSymetrics make money?

Four revenue lines are on record. Defense Collaboration Revenue is the primary driver. The others are pharmaceutical Partnership Agreements, NIH Grant Funding and rare Disease Data Collaboration.

Who are BioSymetrics's main competitors?

Direct peers on record are Schrödinger, XtalPi, Recursion Pharmaceuticals, Insitro, Atomwise and Exscientia. Emerging players are CytoReason, Lantern Pharma and twoXAR Pharmaceuticals. Ginkgo Bioworks is listed as a broad incumbent.

Does BioSymetrics have an API?

No public API is recorded for BioSymetrics.

What industry is BioSymetrics in?

BioSymetrics's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialAI For Drug Development And Discovery - Global Strategic Business Report 2026: Secure $18.1B By 2032 At 31.8% CAGR As Benevolentai, Biosymetrics, Healx And Insilico Medicine Disrupt Drug R&DThe global AI for drug development and discovery market was valued at $2.6 billion in 2025 and is projected to reach $18.1 billion by 2032, a 31.8% CAGR. Growth is driven by predictive molecular design, genomic data, and pressure to reduce R&D costs. The report also forecasts the target identification segment to reach $9.3 billion by 2032.Stock TitanLunai Bioworks Signs Exclusive Tanaist Parkinson’s LicenseLunai Bioworks signed an exclusive worldwide license with Tanaist for cellular phenotyping in Parkinson's programs. The collaboration validates AI-derived subtypes from BioSymetrics' Augusta AI platform against human cellular biology. Lunai will own collaboration-generated results and IP.PRLogLunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist AgreementLunai Bioworks signed a worldwide Tanaist agreement to add human cellular validation to its AI-driven Parkinson's platform, aiming to move from patient subtypes and biomarkers to biological mechanisms and therapeutic targets. The company is positioned for a $400M to $1.2B US Countermeasures Program, and it also named six broker-dealers in an expanded naked short-selling suit.PR NewswireLunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AILunai Bioworks' BioSymetrics subsidiary demonstrated structure-based screening for acetylcholinesterase inhibition using 9,667 compounds, achieving 5.1-fold enrichment. The model's AUROC was 0.88, and the company invites discussions with AI developers like OpenAI and Anthropic.AijournLunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson’s Disease Data Readout Targeted for First Half of 2027Lunai Bioworks Inc. (Nasdaq: LNAI) has executed a Master Collaboration Agreement with BrainStorm Therapeutics Inc. to develop an integrated AI-driven workflow for Parkinson's disease research, combining BioSymetrics' patient-stratification platform with BrainStorm's human midbrain organoid technology. The collaboration targets an initial data readout in the first half of 2027 and follows the publication of a BioSymetrics white paper on Parkinson’s disease subtypes derived from the PPMI dataset. The agreement establishes a three-stage commercial strategy spanning clinical-trial enrichment for pharma partners, biomarker panel development, and partner-ready therapeutic programs using validated human biological systems.Stock TitanLunai Bioworks Signs Parkinson’s Collaboration; 2027 DataLunai Bioworks Inc. (Nasdaq: LNAI) has signed a Master Collaboration Agreement with BrainStorm Therapeutics Inc. to jointly advance Parkinson's disease research, combining BioSymetrics' AI-powered patient-stratification platform with BrainStorm's patient-derived human midbrain organoid technology. The collaboration targets an initial data readout in the first half of 2027 and follows BioSymetrics' publication of a technical white paper identifying clinically distinct Parkinson's disease subtypes from the PPMI dataset. The partnership has a three-stage commercial strategy encompassing clinical-trial design support, biomarker panel development, and generation of partner-ready therapeutic programs for pharmaceutical collaborators.EIN PresswireLunai Bioworks & BrainStorm Therapeutics Launch Foundation-Funded Parkinson’s & Rare Epilepsy AI Discovery CollaborationLunai Bioworks and BrainStorm Therapeutics announced a collaboration and Letter of Intent to jointly discover and validate therapeutic targets for neurological diseases, supported by a LouLou Foundation grant. The partnership combines AI-driven discovery, human organoid systems, and in vivo zebrafish validation, with initial focus on rare epilepsies and Parkinson's disease. The companies aim to generate development-ready programs for pharmaceutical partnering and licensing.PR NewswireLunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under DiscussionLunai Bioworks' subsidiary BioSymetrics has entered into a revenue-generating, multi-year commercial defense collaboration with an unnamed specialized biotechnology partner to deploy an AI-enabled platform for chemical threat assessment, with initial engagement underway and additional engagements under discussion. The platform combines in vivo zebrafish-based phenotypic screening with AI-driven mechanism-of-action prediction to identify and characterize neuroactive and neurotoxic compounds, reportedly capable of evaluating hundreds to thousands of compounds per week. This marks Lunai Bioworks' first revenue-generating defense collaboration, supporting the company's broader strategy to advance dual-use technologies spanning defense and pharmaceutical applications.BioSpaceLunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under DiscussionLunai Bioworks' subsidiary BioSymetrics has entered into its first revenue-generating commercial defense collaboration with an unnamed biotechnology partner to develop an AI-enabled platform for chemical threat assessment. The multi-year agreement deploys BioSymetrics' phenotypic screening and AI capabilities combined with zebrafish-based models to identify and classify neuroactive and neurotoxic compounds for defense applications. The company reports initial engagement is underway and additional defense engagements are currently under discussion.openPR.comComputer Aided Drug Discovery Market 2025-2032 Emerging Trends in Industry Dynamics, Size Insights, Share, and Future Growth | Certara • BioSymetrics • ChemAxonThe article discusses the market analysis of the Computer Aided Drug Discovery industry from 2025 to 2032, highlighting key companies, growth trends, and regional market insights. It emphasizes technological advancements, market forecasts, and strategic corporate initiatives aimed at future growth.